Understanding the Key Points of Kesimpta Prescribing Information for MS Patients
Multiple sclerosis (MS) is a chronic medical condition that affects the central nervous system. It results in various symptoms such as muscle weakness, difficulty with coordination, and blurred vision. The number of people diagnosed with MS has been increasing rapidly over the past few years.
Kesimpta is a drug recently approved by the FDA for the treatment of relapsing multiple sclerosis. It is a self-administered medication that doesn’t require frequent doctor’s visits.
In this article, we’ll explore the critical aspects of the prescribing information for Kesimpta for MS patients.
How does Kesimpta work?
Kesimpta is a monoclonal antibody that binds to a specific protein called CD20 on the surface of B cells. B cells play a crucial role in the immune system by producing antibodies that fight infections. However, in MS patients, B cells attack healthy nerve cells, leading to nerve damage and inflammation.
By binding to CD20, Kesimpta eliminates B cells from the bloodstream, reducing B cell activity and inflammation in the brain and spinal cord.
Who can take Kesimpta?
Kesimpta is indicated for the treatment of relapsing forms of MS in adults. It is not recommended for individuals with primary progressive MS.
Before prescribing Kesimpta, doctors should evaluate patients with a recent MRI of the brain and inform them about the potential risks and benefits of the drug.
How is Kesimpta administered?
Kesimpta is administered as a subcutaneous injection. Patients are required to take the medication once a month.
The first injection should be administered under the supervision of a healthcare professional to monitor for potential allergic reactions. After that, patients can self-administer the medication at home.
What are the potential side effects of Kesimpta?
Like all medications, Kesimpta may cause adverse reactions. The most common side effects reported in clinical trials include headaches, upper respiratory infections, and injection site reactions.
More severe side effects such as infections, cancer, and an increased risk of progressive multifocal leukoencephalopathy (PML) have also been reported. Patients must be aware of these potential risks and discuss them with their doctor before starting the medication.
Conclusion
Kesimpta offers a unique and effective treatment for MS patients. It is essential to understand the prescribing information for this medication before starting the treatment to ensure the best possible outcome.
Patients should also consider the potential risks and benefits of Kesimpta carefully, discuss them with their doctor, and closely monitor their health for any side effects. By providing critical insights on Kesimpta, we hope to have increased awareness and knowledge of this medication among patients and healthcare professionals alike.
